Search

Displaying results 2221 - 2230 of 10000 in total
  1. Drug

    Trazodone

    go.drugbank.com/drugs/DB00656
    ApprovedInvestigational

    receptor inhibitor (SNRIs) in the treatment of depression. … [T646] It was initially granted FDA approval in 1981.[L3484]

  2. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.

    Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
  3. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

  4. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    in combination with sofosbuvir for all six genotypes of Hepatitis C [L852]. … It is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and

  5. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    In fact, administration of T3 may result in supratherapeutic levels of T3. … It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues.

  6. Drug

    Lenograstim

    go.drugbank.com/drugs/DB13144
    ApprovedWithdrawn

    Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

  7. Drug

    Strontium chloride

    go.drugbank.com/drugs/DB13987
    ApprovedWithdrawn

    SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. … Such strontium chloride toothpaste formulations may subsequently not be available for sale anymore in certain parts of the world [A33167, A33168].

  8. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab was granted FDA approval on April 9,2019[L5921]. … Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant

    Products: EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML, EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105MG/1.17ML
  9. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.

    Mixtures: PRESOMEN 28 COMP 0.3/5MG, PRESOMEN 28 COMP 0.3/5MG
  10. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019. … [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug